Physician profile
Amy Smith
NPI 1457655359
$1,369.37
in general payments reported to CMS, 2019-2025
11 companies · $32.31 in 2025
The $32.31 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $563 · 2023: $213 · 2024: $225 · 2025: $32.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $454.73 | 2021-2024 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $311.05 | 2021-2025 | |
| Abbott Laboratories | $211.58 | 2022-2023 | Proclaim |
| Amgen INC. | $154.07 | 2022-2024 | Otezla |
| Pfizer INC. | $50.55 | 2022 | |
| Genentech USA, INC. | $44.13 | 2021-2023 | Xolair |
| Novo Nordisk INC | $39.38 | 2021 | |
| Glaxosmithkline, LLC. | $32.50 | 2023-2025 | Pediarix, Bexsero, Penmenvy |
| Dermavant Sciences, INC. | $30.50 | 2023 | Vtama |
| Abbvie INC. | $24.20 | 2022 | |
| Boston Scientific Corporation | $16.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.